Previous work found referrals for end-of-life care are made late in the dying process and assessment processes for care funding, through continuing healthcare fast-track funding often inhibit people being able to die at home. The average time to discharge was 6.3 days and 29% died in hospital, as median survival was only 15 days.We aimed to support discharge to home within 1 day by December 2023 for patients, wishing to die at home, referred to the end-of-life discharge team in a medium-sized district general hospital in Southwest England.In phase 1, we identified 13 people on a patient-by-patient basis, learning from obstacles. Barriers identified included sourcing of equipment, communication between teams and clunky paperwork. Median time to discharge was 2 days (range within 24 hours to 8 days) with 2/13 (15.4%) dying prior to discharge. In phase 2, we extended the pilot, and 104 patients were identified; 94 people were discharged to home, with a median of wait of 1 day (range 0-7) to discharge, and 10 (9.6%) died prior to discharge (median 1 day; range 0-4). Median survival from discharge for the 94 who achieved their wishes to go home to die was 9 days (range 1-205 days). Only 26/94 (27.7%) people survived more than 30 days.Rapid decision-making and structures to support home-based end-of-life care can support more people to die in their preferred place of care, by using a community-based rapid response team instead of, or in parallel with continuing healthcare fast-track funding referral applications. Current pathways and funding models are not fit for purpose in an urgent care scenario when we have only one chance to get it right.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141173 | PMC |
http://dx.doi.org/10.1136/bmjoq-2024-002790 | DOI Listing |
J Adv Nurs
January 2025
School of Nursing and Midwifery, Sub-Faculty of Health Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
Aim: To explore the experiences of emergency nurses providing end-of-life care during the COVID-19 pandemic.
Design: A qualitative descriptive study.
Methods: Data were collected between May and August 2023.
Ecancermedicalscience
November 2024
Department of Community Health and Primary Care, College of Medicine, University of Lagos, Idi-araba, Lagos 101017, Nigeria.
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect associated with chemotherapy. It can lead to detrimental dose reductions and discontinuation of treatment because of its significant effect, which impairs the quality of life among the surviving population of cancer patients. This study assesses the prevalence and predictors of CIPN among female breast cancer patients receiving chemotherapy at the Lagos University Teaching Hospital and Lagos State University Teaching Hospital (LUTH and LASUTH), respectively.
View Article and Find Full Text PDFFront Antibiot
June 2024
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Orthotopic liver transplant (OLT) represents the standard of care for managing patients affected by end-stage and life-threatening liver diseases. Although a significant improvement in surgical techniques, immunosuppressant regimens, and prompt identification of early post-transplant complications resulted in better clinical outcome and survival in OLT recipients, the occurrence of early bacterial infections still represents a remarkable cause of morbidity and mortality. In this scenario, beta-lactams are the most frequent antimicrobials used in critical OLT recipients.
View Article and Find Full Text PDFJ Intellect Dev Disabil
December 2024
Department of Nursing, Ōtākou Whakaihu Waka | University of Otago, Dunedin, New Zealand.
Background: People with intellectual disabilities have traditionally been excluded from Advance Care (AC) planning. This study aimed to improve access to and the quality of AC planning for this community.
Method: A Participatory Action Research study was led, and participated in, by co-researchers with intellectual disabilities and disability service managers.
J Pathol
January 2025
Cardiorenal Translational Laboratory, Imas12 Research Institute, Hospital Universitario 12 de Octubre, Madrid, Spain.
Ischaemic heart disease (IHD) remains a major cause of death and morbidity. Klotho is a well-known anti-ageing factor with relevant cardioprotective actions, at least when renal dysfunction is present, but its actions are much less known when renal function is preserved. This study investigated Klotho as a biomarker and potential novel treatment of IHD-associated complications after myocardial infarction (MI) under preserved renal function.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!